Origami Therapeutics Analysis: $125K Raised
What is Origami Therapeutics?
Origami Therapeutics develops therapies targeting and degrading disease-related proteins to treat neurodegenerative diseases like Alzheimer's, Huntington's, and Parkinson's.
Employees
4
Founded
2015
Revenue
$1-5M
Product Features & Capabilities
- disease-modifying protein degraders, therapies targeting and degrading disease-related proteins, selective and efficient degradation of disease-causing proteins, small molecules for broad distribution and ease of manufacture, focus on neurodegenerative diseases including Alzheimer's, Huntington's, P
How much Origami Therapeutics raised
1: - $125K
2022Lead Investor: Y Combinator
Who are the founders of Origami Therapeutics
BH
Beth Hoffman
Founder
Market Focus
Origami Therapeutics primarily focuses on the biotechnology industry, specifically developing therapies for neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's.
Investors
- Y Combinator
- JLABS
- THE CATALYTIC IMPACT FOUNDATION (CIF)
- California Life Sciences
- U.S. Department of Health and Human Services
- Creative Destruction Lab
Competitors Overview
Origami Therapeutics operates in the neurodegenerative disease treatment market, focusing on developing next-generation therapies that target and degrade disease-related proteins. Its main competitors include:
- Biogen: Founded in 1978, Biogen is a well-established public company based in Camb
See something that needs updating? Suggest edits to this profile.